应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02480 绿竹生物-B
已收盘 02-19 16:08:20
22.200
+0.750
+3.50%
最高
22.200
最低
21.500
成交量
2,400
今开
22.100
昨收
21.450
日振幅
3.26%
总市值
44.62亿
流通市值
44.62亿
总股本
2.01亿
成交额
5.19万
换手率
0.00%
流通股本
2.01亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
绿竹生物-B盘中异动 股价大跌9.55%
市场透视 · 02-14
绿竹生物-B盘中异动 股价大跌9.55%
又一款国产带状疱疹疫苗申报上市 中老年人的接种市场仍待撬开
第一财经 · 02-10
又一款国产带状疱疹疫苗申报上市 中老年人的接种市场仍待撬开
绿竹生物-B:LZ901生物制品许可申请获国家药监局受理
新浪网 · 02-10
绿竹生物-B:LZ901生物制品许可申请获国家药监局受理
绿竹生物核心产品BLA许可申请获国家药监局受理
财中社 · 02-09
绿竹生物核心产品BLA许可申请获国家药监局受理
【绿竹生物-B(02480.HK):LZ901生物制品许可申请获国家药监局受理】绿竹生物-B(02480.HK)发布公告,于近日,集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。
金融界 · 02-09
【绿竹生物-B(02480.HK):LZ901生物制品许可申请获国家药监局受理】绿竹生物-B(02480.HK)发布公告,于近日,集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。
绿竹生物-B(02480):LZ901生物制品许可申请获国家药监局受理
智通财经 · 02-09
绿竹生物-B(02480):LZ901生物制品许可申请获国家药监局受理
绿竹生物-B盘中异动 早盘股价大涨5.79%报25.600港元
市场透视 · 02-03
绿竹生物-B盘中异动 早盘股价大涨5.79%报25.600港元
绿竹生物-B盘中异动 早盘大幅拉升5.01%报24.100港元
市场透视 · 01-27
绿竹生物-B盘中异动 早盘大幅拉升5.01%报24.100港元
绿竹生物-B盘中异动 股价大涨5.69%报23.200港元
市场透视 · 01-14
绿竹生物-B盘中异动 股价大涨5.69%报23.200港元
绿竹生物-B盘中异动 股价大涨5.50%
市场透视 · 01-13
绿竹生物-B盘中异动 股价大涨5.50%
绿竹生物-B盘中异动 股价大跌5.88%
市场透视 · 01-10
绿竹生物-B盘中异动 股价大跌5.88%
绿竹生物-B(02480)股价下跌5.882%,现价港币$20.0
阿斯达克财经 · 01-10
绿竹生物-B(02480)股价下跌5.882%,现价港币$20.0
绿竹生物-B盘中异动 下午盘急速跳水6.07%报20.100港元
市场透视 · 01-08
绿竹生物-B盘中异动 下午盘急速跳水6.07%报20.100港元
绿竹生物-B盘中异动 股价大跌9.59%报20.750港元
市场透视 · 01-02
绿竹生物-B盘中异动 股价大跌9.59%报20.750港元
绿竹生物-B盘中异动 早盘股价大涨5.41%报23.400港元
市场透视 · 2024-12-30
绿竹生物-B盘中异动 早盘股价大涨5.41%报23.400港元
绿竹生物-B盘中异动 早盘急速下跌6.67%报21.000港元
市场透视 · 2024-12-24
绿竹生物-B盘中异动 早盘急速下跌6.67%报21.000港元
绿竹生物-B股价重挫11.65% 市值跌5.15亿港元
市场透视 · 2024-12-20
绿竹生物-B股价重挫11.65% 市值跌5.15亿港元
创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力
金吾财讯 · 2024-12-18
创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力
绿竹生物-B盘中异动 早盘大幅拉升6.17%报25.800港元
市场透视 · 2024-12-18
绿竹生物-B盘中异动 早盘大幅拉升6.17%报25.800港元
绿竹生物-B股价重挫14.04% 市值跌6.22亿港元
市场透视 · 2024-12-16
绿竹生物-B股价重挫14.04% 市值跌6.22亿港元
加载更多
公司概况
公司名称:
绿竹生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
北京绿竹生物技术股份有限公司是一家主要从事药物发现、研究及开发及商业化的中国公司。该公司还从事对外授权人类疫苗及治疗性生物制剂。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02480","market":"HK","secType":"STK","nameCN":"绿竹生物-B","latestPrice":22.2,"timestamp":1739952500015,"preClose":21.45,"halted":0,"volume":2400,"delay":0,"floatShares":201013032,"shares":201013032,"eps":-1.3382590179725473,"marketStatus":"已收盘","change":0.75,"latestTime":"02-19 16:08:20","open":22.1,"high":22.2,"low":21.5,"amount":51860,"amplitude":0.032634,"askPrice":22.45,"askSize":200,"bidPrice":20.9,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":-1.4753755719329626,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1740015000000},"marketStatusCode":5,"adr":0,"listingDate":1683475200000,"exchange":"SEHK","adjPreClose":21.45,"openAndCloseTimeList":[[1739928600000,1739937600000],[1739941200000,1739952000000]],"volumeRatio":0.967742,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02480","defaultTab":"news","newsList":[{"id":"2511582766","title":"绿竹生物-B盘中异动 股价大跌9.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511582766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511582766?lang=zh_cn&edition=full","pubTime":"2025-02-14 14:44","pubTimestamp":1739515472,"startTime":"0","endTime":"0","summary":"2025年02月14日下午盘14时44分,绿竹生物-B股票出现异动,股价快速跳水9.55%。绿竹生物-B股票所在的生物技术行业中,整体涨幅为3.23%。其相关个股中,维亚生物、华领医药-B、晶泰控股-P涨幅较大,振幅较大的相关个股有维亚生物、方达控股、中国抗体-B,振幅分别为20.41%、18.24%、14.29%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214144432962299c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214144432962299c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2510580885","title":"又一款国产带状疱疹疫苗申报上市 中老年人的接种市场仍待撬开","url":"https://stock-news.laohu8.com/highlight/detail?id=2510580885","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510580885?lang=zh_cn&edition=full","pubTime":"2025-02-10 14:11","pubTimestamp":1739167895,"startTime":"0","endTime":"0","summary":"【又一款国产带状疱疹疫苗申报上市 中老年人的接种市场仍待撬开】2月9日晚间,绿竹生物(02480.HK)发布了其重组带状疱疹疫苗LZ901上市申请获得国家药监局受理消息。如顺利上市的话,这款疫苗将成为在国内上市的第三款带状疱疹疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502103314877975.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502103314877975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2510607276","title":"绿竹生物-B:LZ901生物制品许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2510607276","media":"新浪网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510607276?lang=zh_cn&edition=full","pubTime":"2025-02-10 09:14","pubTimestamp":1739150070,"startTime":"0","endTime":"0","summary":"绿竹生物-B发布公告,于近日,集团的重组带状疱疹疫苗及核心产品LZ901的生物制品许可申请获得了中国国家药品监督管理局受理。LZ901是集团自主开发的重组带状疱疹疫苗,并且是集团的核心产品,旨在预防年龄为40岁及以上成人带状疱疹及带状疱疹引致的相关并发症的发生。LZ901于中国的III期临床试验已达到临床预设目标,并取得符合预期的临床结果。请读者仅作参考,并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210093226961d49e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210093226961d49e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2510588045","title":"绿竹生物核心产品BLA许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2510588045","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510588045?lang=zh_cn&edition=full","pubTime":"2025-02-09 20:21","pubTimestamp":1739103684,"startTime":"0","endTime":"0","summary":"财中社2月9日电绿竹生物-B(02480)发布公告,近日公司核心产品LZ901的生物制品许可申请(BLA)已获得中华人民共和国国家药监局受理。这一进展标志着公司在重组带状疱疹疫苗(CHO细胞)的研发过程中迈出了重要一步。LZ901旨在预防40岁及以上成人带状疱疹及其相关并发症,包括带状疱疹后遗神经痛,且在中国的III期临床试验中已达到预设目标并取得符合预期的临床结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502093314223646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2510010979","title":"【绿竹生物-B(02480.HK):LZ901生物制品许可申请获国家药监局受理】绿竹生物-B(02480.HK)发布公告,于近日,集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510010979","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510010979?lang=zh_cn&edition=full","pubTime":"2025-02-09 18:50","pubTimestamp":1739098235,"startTime":"0","endTime":"0","summary":"绿竹生物-B(02480.HK)发布公告,于近日,集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/09185048038880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","159646","02480"],"gpt_icon":0},{"id":"2510108970","title":"绿竹生物-B(02480):LZ901生物制品许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2510108970","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510108970?lang=zh_cn&edition=full","pubTime":"2025-02-09 18:46","pubTimestamp":1739097976,"startTime":"0","endTime":"0","summary":"智通财经APP讯,绿竹生物-B(02480)发布公告,于近日,集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。LZ901是集团自主开发的重组带状疱疹疫苗(CHO细胞),并且是集团的核心产品,旨在预防年龄为40岁及以上成人带状疱疹及带状疱疹引致的相关并发症的发生(包括带状疱疹后遗神经痛)。LZ901于中国的III期临床试验已达到临床预设目标,并取得符合预期的临床结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2508165508","title":"绿竹生物-B盘中异动 早盘股价大涨5.79%报25.600港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508165508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508165508?lang=zh_cn&edition=full","pubTime":"2025-02-03 09:53","pubTimestamp":1738547637,"startTime":"0","endTime":"0","summary":"2025年02月03日早盘09时53分,绿竹生物-B股票出现波动,股价快速上涨5.79%。截至发稿,该股报25.600港元/股,成交量600股,换手率0.00%,振幅5.79%。资金方面,该股资金流入1.012万港元,流出0港元。绿竹生物-B股票所在的生物技术行业中,整体跌幅为2.12%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203095357a237758a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203095357a237758a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2506313303","title":"绿竹生物-B盘中异动 早盘大幅拉升5.01%报24.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506313303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506313303?lang=zh_cn&edition=full","pubTime":"2025-01-27 09:36","pubTimestamp":1737941799,"startTime":"0","endTime":"0","summary":"2025年01月27日早盘09时36分,绿竹生物-B股票出现波动,股价快速上涨5.01%。截至发稿,该股报24.100港元/股,成交量600股,换手率0.00%,振幅3.27%。资金方面,该股资金流入1.424万港元,流出0港元。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.17%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012709363996119535&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012709363996119535&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2503506988","title":"绿竹生物-B盘中异动 股价大涨5.69%报23.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503506988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503506988?lang=zh_cn&edition=full","pubTime":"2025-01-14 09:30","pubTimestamp":1736818255,"startTime":"0","endTime":"0","summary":"2025年01月14日早盘09时30分,绿竹生物-B股票出现异动,股价急速拉升5.69%。截至发稿,该股报23.200港元/股,成交量800股,换手率0.00%,振幅2.28%。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.75%。其相关个股中,方达控股、宜明昂科-B、绿竹生物-B涨幅较大,振幅较大的相关个股有宜明昂科-B、康诺亚-B、药明合联,振幅分别为3.91%、3.19%、2.94%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140930559602c117&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140930559602c117&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2503312695","title":"绿竹生物-B盘中异动 股价大涨5.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503312695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503312695?lang=zh_cn&edition=full","pubTime":"2025-01-13 09:39","pubTimestamp":1736732392,"startTime":"0","endTime":"0","summary":"2025年01月13日早盘09时39分,绿竹生物-B股票出现波动,股价急速上涨5.50%。截至发稿,该股报21.100港元/股,成交量400股,换手率0.00%,振幅1.50%。绿竹生物-B股票所在的生物技术行业中,整体跌幅为0.41%。绿竹生物-B公司简介:北京绿竹生物技术股份有限公司是一家主要从事药物发现、研究及开发及商业化的中国公司。该公司还从事对外授权人类疫苗及治疗性生物制剂。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113093952a21f7973&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113093952a21f7973&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2502896383","title":"绿竹生物-B盘中异动 股价大跌5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502896383","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502896383?lang=zh_cn&edition=full","pubTime":"2025-01-10 13:35","pubTimestamp":1736487357,"startTime":"0","endTime":"0","summary":"2025年01月10日下午盘13时35分,绿竹生物-B股票出现异动,股价快速下跌5.88%。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.15%。其相关个股中,药明合联、巨子生物、永泰生物-B涨幅较大,振幅较大的相关个股有同源康医药-B、北海康成-B、晶泰控股-P,振幅分别为36.98%、21.85%、11.88%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011013355795fecd9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011013355795fecd9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2502886511","title":"绿竹生物-B(02480)股价下跌5.882%,现价港币$20.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2502886511","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502886511?lang=zh_cn&edition=full","pubTime":"2025-01-10 13:35","pubTimestamp":1736487300,"startTime":"0","endTime":"0","summary":"[下跌股]绿竹生物-B(02480) 股价在下午01:35比前收市价下跌5.882%,现股价为港币$20.0。至目前为止,今日最高价为$20.8,而最低价为$20.0。总成交量为3000股,总成交金额为港币$6.016万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2501101406/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2501700719","title":"绿竹生物-B盘中异动 下午盘急速跳水6.07%报20.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501700719","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501700719?lang=zh_cn&edition=full","pubTime":"2025-01-08 15:24","pubTimestamp":1736321099,"startTime":"0","endTime":"0","summary":"2025年01月08日下午盘15时24分,绿竹生物-B股票出现波动,股价大幅跳水6.07%。截至发稿,该股报20.100港元/股,成交量600股,换手率0.00%,振幅5.84%。资金方面,该股资金流入8470港元,流出4020港元。绿竹生物-B股票所在的生物技术行业中,整体跌幅为1.05%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815245995fc8363&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815245995fc8363&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2500915642","title":"绿竹生物-B盘中异动 股价大跌9.59%报20.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500915642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500915642?lang=zh_cn&edition=full","pubTime":"2025-01-02 15:06","pubTimestamp":1735801561,"startTime":"0","endTime":"0","summary":"2025年01月02日下午盘15时06分,绿竹生物-B股票出现波动,股价大幅下挫9.59%。截至发稿,该股报20.750港元/股,成交量400股,换手率0.00%,振幅9.80%。绿竹生物-B股票所在的生物技术行业中,整体跌幅为1.02%。其相关个股中,华康生物医学、嘉和生物-B、思路迪医药股份涨幅较大,振幅较大的相关个股有华康生物医学、北海康成-B、华昊中天医药-B,振幅分别为29.33%、29.32%、20.81%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010215060195f625ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010215060195f625ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2495569556","title":"绿竹生物-B盘中异动 早盘股价大涨5.41%报23.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495569556","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495569556?lang=zh_cn&edition=full","pubTime":"2024-12-30 11:26","pubTimestamp":1735529161,"startTime":"0","endTime":"0","summary":"2024年12月30日早盘11时26分,绿竹生物-B股票出现波动,股价大幅拉升5.41%。截至发稿,该股报23.400港元/股,成交量3800股,换手率0.00%,振幅6.31%。资金方面,该股资金流入8.488万港元,流出0港元。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.06%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123011260298546cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123011260298546cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2493286077","title":"绿竹生物-B盘中异动 早盘急速下跌6.67%报21.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493286077","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493286077?lang=zh_cn&edition=full","pubTime":"2024-12-24 10:57","pubTimestamp":1735009075,"startTime":"0","endTime":"0","summary":"2024年12月24日早盘10时57分,绿竹生物-B股票出现异动,股价大幅下跌6.67%。截至发稿,该股报21.000港元/股,成交量2200股,换手率0.00%,振幅3.56%。资金方面,该股资金流入4.78万港元,流出0港元。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.25%。该公司还从事对外授权人类疫苗及治疗性生物制剂。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224105755ab8f8390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224105755ab8f8390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2492880455","title":"绿竹生物-B股价重挫11.65% 市值跌5.15亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492880455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492880455?lang=zh_cn&edition=full","pubTime":"2024-12-20 10:13","pubTimestamp":1734660788,"startTime":"0","endTime":"0","summary":"2024年12月20日早盘10时13分,绿竹生物-B股票出现异动,股价大幅下跌11.65%。截至发稿,该股报22.000港元/股,成交量800股,换手率0.00%,振幅15.66%。资金方面,该股资金流入1.468万港元,流出0港元。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.09%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220101308984ce5c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220101308984ce5c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2492941582","title":"创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2492941582","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492941582?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:55","pubTimestamp":1734486946,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念多数上扬,圣诺医药 涨11.56%,百奥赛图涨9.68%,歌礼制药涨7.98%,绿竹生物涨4.73%,再鼎医药涨4.41%,康诺亚涨1.34%,中国生物制药涨0.95%,信达生物涨0.69%银河证券表示,1)医药创新是医药增长的核心动力。对于医药板块, 在“医保+商保”模式不断推进、政策支持等因素驱动下,行业规模有望进一步扩大。“医保+商保”模式打开健康险空间,创新药发展空间更大。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1949850","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","LU1969619763.USD","02315","BK1161","01672","02480","01801","02162","01177","159992","06978","02257","159938","BK1589","BK1521","BK1191","BK1583","LU2328871848.SGD","LU2488822045.USD","BK1587","09688","BK1588","09939"],"gpt_icon":0},{"id":"2492794998","title":"绿竹生物-B盘中异动 早盘大幅拉升6.17%报25.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492794998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492794998?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:33","pubTimestamp":1734485632,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘09时33分,绿竹生物-B股票出现波动,股价大幅上涨6.17%。截至发稿,该股报25.800港元/股,成交量400股,换手率0.00%,振幅3.29%。资金方面,该股资金流入1.016万港元,流出0港元。绿竹生物-B股票所在的生物技术行业中,整体涨幅为0.11%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218093357ab807d44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218093357ab807d44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2491666634","title":"绿竹生物-B股价重挫14.04% 市值跌6.22亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491666634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491666634?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:46","pubTimestamp":1734328012,"startTime":"0","endTime":"0","summary":"2024年12月16日下午盘13时46分,绿竹生物-B股票出现波动,股价快速跳水14.04%。截至发稿,该股报22.050港元/股,成交量1800股,换手率0.00%,振幅15.01%。资金方面,该股资金流入2.072万港元,流出2.205万港元。绿竹生物-B股票所在的生物技术行业中,整体跌幅为1.09%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216134652a1f22803&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216134652a1f22803&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0}],"profile":{"websiteUrl":"http://luzhubiotech.com","stockEarnings":[{"period":"1week","weight":-0.1173},{"period":"1month","weight":-0.0613},{"period":"3month","weight":0.0239},{"period":"6month","weight":-0.0633},{"period":"1year","weight":-0.2056},{"period":"ytd","weight":-0.0654}],"compareEarnings":[{"period":"1week","weight":0.079},{"period":"1month","weight":0.1732},{"period":"3month","weight":0.166},{"period":"6month","weight":0.3025},{"period":"1year","weight":0.4222},{"period":"ytd","weight":0.1454}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京绿竹生物技术股份有限公司是一家主要从事药物发现、研究及开发及商业化的中国公司。该公司还从事对外授权人类疫苗及治疗性生物制剂。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","exchange":"SEHK","name":"绿竹生物-B","nameEN":"LUZHU BIOTECH-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.1","shortVersion":"4.31.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿竹生物-B,02480,绿竹生物-B股票,绿竹生物-B股票老虎,绿竹生物-B股票老虎国际,绿竹生物-B行情,绿竹生物-B股票行情,绿竹生物-B股价,绿竹生物-B股市,绿竹生物-B股票价格,绿竹生物-B股票交易,绿竹生物-B股票购买,绿竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}